Mohapatra Pradhyumn K, Pachuau Elsa, Kumar Chandra, Borkakoty Biswajit, Zomawia Eric, Singh Achouba, Walia Kamini, Arora Rashmi, Mahanta Jagdish, Subbarao Sarala K
Regional Medical Research Centre (ICMR), Dibrugarh, India.
Department of Pathology, Civil Hospital, Aizawl, India.
Indian J Med Res. 2017 Mar;145(3):387-394. doi: 10.4103/ijmr.IJMR_1427_15.
BACKGROUND & OBJECTIVES: The interactions between HIV and malaria co-infection have been shown to influence each other in their clinical outcomes in Sub-Saharan Africa. This study was carried out in the two States of north east India endemic for both HIV and malaria infections, to study the interactions between the two diseases in the HIV-infected population.
In this prospective study, a total of 333 HIV-infected individuals were followed up for a period of 6-18 months in Mizoram and Manipur during 2010-2011. The study assessed the changes in viral load and also the therapeutic efficacy of artesunate plus sulphadoxine-pyrimethamine (AS+SP) combination therapy in HIV-infected and HIV-uninfected individuals with Plasmodium falciparum malaria.
Viral load in HIV-infected malaria patients on day zero (D0) ranged from 1110 to 147,000 copies/ml. The log transformation of the geometric means of HIV viral loads revealed no significant difference on different days of follow up. There was 100 per cent adequate clinical and parasitological response (ACPR) after treating with artemisinin based combination therapy (ACT) both in HIV-infected and HIV-uninfected P. falciparum-positive individuals. Similarly, chloroquine showed 100 per cent ACPR in P. vivax HIV-infected individuals.
INTERPRETATION & CONCLUSION: The study showed no significant increase in HIV viral load in malaria cases. All HIV-infected and HIV-uninfected P. falciparum malaria-positive cases responded to the treatment with 100 per cent ACPR.
在撒哈拉以南非洲地区，已证实艾滋病毒与疟疾合并感染之间的相互作用会影响彼此的临床结局。本研究在印度东北部两个艾滋病毒和疟疾均为地方病的邦开展，旨在研究艾滋病毒感染者中这两种疾病之间的相互作用。
在这项前瞻性研究中，2010年至2011年期间，在米佐拉姆邦和曼尼普尔邦对总共333名艾滋病毒感染者进行了为期6至18个月的随访。该研究评估了病毒载量的变化，以及青蒿琥酯加磺胺多辛 - 乙胺嘧啶（AS + SP）联合疗法对感染恶性疟原虫的艾滋病毒感染者和未感染艾滋病毒者的治疗效果。
艾滋病毒感染的疟疾患者在第0天（D0）的病毒载量范围为1110至147,000拷贝/毫升。艾滋病毒病毒载量几何均值的对数转换在随访的不同天数显示无显著差异。在感染恶性疟原虫的艾滋病毒感染者和未感染艾滋病毒者中，基于青蒿素的联合疗法（ACT）治疗后临床和寄生虫学反应充分率（ACPR）均为100%。同样，氯喹在感染间日疟原虫的艾滋病毒感染者中ACPR为100%。
该研究表明疟疾病例中艾滋病毒病毒载量无显著增加。所有感染艾滋病毒和未感染艾滋病毒的恶性疟原虫疟疾阳性病例对治疗的ACPR均为100%。
